TY - JOUR. T1 - A novel CSF‐1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma. AU - Baker, A. H.. AU - Cachia, P. G.. AU - Tennant, G. B.. AU - Whittaker, J. A.. AU - White, D.. AU - Stanley, E. R.. AU - Burnett, A. K.. AU - Padua, R. A.. PY - 1995/1. Y1 - 1995/1. N2 - Summary. A novel colony stimulating factor‐1 (CSF‐1) binding factor present in the serum from a patient in remission from lymphoma is described. Radioimmunoassay (RIA) repeatedly failed to detect circulating levels of CSF‐1 in the peripheral blood system of this patient. Molecular analysis showed a normal CSF‐1 gene structure by Southern blot analysis and a 46, XX karyotype by cytogenetic analysis. CSF‐1 mRNA expression in peripheral blood leucocytes was confirmed using reverse transcriptase polymerase chain reaction analysis. Morphological analysis of bone marrow cells was normal and peripheral blood progenitor cell colony assays showed a pattern of growth within the normal ...
Researchers have learned that the best way to cure patients with adult ALL is to administer large doses of several chemotherapeutic drugs over a short period of time. The concept is to kill leukemia cells quickly before resistance to the drugs occurs. Therapy is divided into two phases, remission induction and post-remission therapy. Remission induction…
Six hundred and nineteen patients with de novo acute myeloid leukaemia, entered into the Medical Research Councils eighth trial of therapy have been studied. All patients were treated with the same remission induction regimen. Pretreatment variables comprising age, clinical status, haematological status and a detailed marrow cytology and cytochemistry score have been analysed. Poorer remission rates have been found in older patients, in those with lower Karnofsky scores and in patients with a platelet count of less than 25 X 10(9)/l. Leukaemias showing evidence of cytoplasmic maturation along the granulocyte and monocyte lines, as evidenced by granules, Auer rods, a high percentage of Sudan black positive blast cells and morphological and cytochemical abnormalities of neutrophils were associated with a higher remission rate. Marrow eosinophilia was a good prognostic feature. Nuclear features of immaturity, i.e. increasing numbers and prominence of nucleoli were associated with a low remission rate.
If a complete remission is achieved following remission induction therapy and no further treatment given, over 90% of patients will have a recurrence of leukemia in weeks to months. However, treatment with standard intensive post-remission therapy can now cure 25-35% of adults with ALL. It is important to understand what determines the success or failure…
The data reviewed indicate substantial recent progress in the treatment of ALL in adults. Most patients, greater than 70% to 80%, will achieve a remission following induction chemotherapy with vincristine, prednisone, and an anthracycline. Additional drugs do not convincingly increase the remission rate; their effect on remission duration is unknown. Although continuation therapy has not been critically evaluated in randomized trials, the longest remissions have been reported in individuals receiving consolidation/intensification, particularly in the immediate postremission period. Presently, a disease-free survival is 35% to 45% at greater than 5 years when this type of consolidation/intensification therapy is used. The precise value of conventional maintenance chemotherapy in adult ALL is unknown. CNS prophylaxis is necessary; the standard of treatment remains cranial radiation and intrathecal methotrexate. Alternative approaches are currently being studied such as systemic treatment with high ...
Inclusion Criteria: - Patients must have a histologically and cytological confirmed acute myeloid leukemia, high risk AML defined as: - Age , 60, or - Presence of complex cytogenetic abnormalities (with , 3 cytogenetic abnormalities), del (7q, -5, -7), t(9,22), 11q(23) or high risk mutations by FISH eg MLL, FLT-3 + - Secondary AML, or - A white blood cell count of , 50 x10^9/L - Patients must be medically ineligible for allogeneic stem cell transplant (alloSCTx) or not have a known fully HLA matched sibling for planned sibling transplant. - Patients must have measurable or evaluable disease - Diagnosis of AML according to World Health Organization (WHO) diagnostic criteria (at least 20% blasts in the peripheral blood or bone marrow), with French-American-British Cooperative group (FAB) classification other than M3 (acute promyelocytic leukemia), documented by bone marrow aspiration and biopsy performed within 14 days prior to administration of 1st dose of remission induction chemotherapy; if a ...
Objectives Combination therapy with methotrexate (MTX) and tumour necrosis factor (TNF) blockade has increased remission rates in patients with rheumatoid arthritis. However, there are no guidelines regarding cessation of therapy. There is a need for markers predictive of sustained remission following cessation of TNF blocker therapy.. Methods Patients in remission (DAS28 ,2.6) treated with a TNF blocker and MTX as initial or delayed therapy were recruited. Joints were assessed for grey scale synovitis and power Doppler (PD) activity. Immunological assessment involved advanced six-colour flow cytometry.. Results Of the 47 patients recruited, 27 had received initial treatment and 20 delayed treatment with TNF blocking drugs. Two years after stopping TNF blocker therapy, the main predictor of successful cessation was timing of treatment; 59% of patients in the initial treatment group sustained remission compared with 15% in the delayed treatment group (p=0.003). Within the initial treatment group, ...
Ive been better since my last post - only sick a handful of times and those were all acidy-tummy-up sicks and gorged-myself-stupid sicks. No cancer tummy-up-sicks - which is a huge relief seeing as I am considered to be in REMISSION. Ben Vet said to Meowmie that he considered me to be in Clinical Remission - he sounded very sure about it this time, so I am going to state it here in my blog too - he has said it before now, quite some time ago, but he seemed quite definite yesterday when I was there for my Vincristine so I am confident to share the good news ...
Vaccination of AML patients in remission with WT1 mRNA-electroporated DCs lead to improved OS rates, which correlated with the induction of WT1-specific CD8+ T-cell responses.
Induction chemotherapy: Three drug induction therapy using vincristine, prednisolone/ dexamethasone, L-asparaginase in conjunction with intrathecal therapy results in complete remission rate of greater than 95%. For patients with high risk, an anthracycline (daunorubicin) may be included. The aim of induction phase is to induce remission. In general, patients will achieve complete remission within the first 4 weeks. Patients who require more than 4 weeks to achieve remission or those who demonstrate more than 25% blasts in the bone marrow or have persistent blasts in the peripheral blood after 1 week of intensive induction therapy have a poor prognosis. (A bone marrow is done at the end of induction to establish remission status ...
Consolidation treatment of acute myeloid leukemia (AML) (costs for program #115409) ✔ Academic Hospital Harlaching ✔ Department of Pediatrics ✔ BookingHealth.com
ATLANTA -- New criteria to define clinical remission in rheumatoid arthritis, endorsed by two major specialty groups, provide a realistic standard for drug trials and give clinicians a better guide fo
According to the NCI, remission is different from being cancer-free. Remission means that the signs and symptoms of your cancer are reduced or gone, and the remission can be partial or complete. If you remain in complete remission for five years or more, some doctors may say that you are cured, or cancer-free.. ...
Review clinical trial data including remission across measures with or without MTX and remission rates up to 1 year (DAS28-CRP|2.6). See Important Safety Information, including BOXED WARNING.
English examples for remission - Not long after this, her son went into remission and returned to work. The disease may also go into remission for a time, or may be permanent. She eventually had her breast removed and has been in remission since.
When discussing cancer treatment, its important to use caution when discussing whether a persons cancer is cured. More often, youll see that the term remission is used.. A remission is when cancer symptoms are significantly reduced. Its possible for remission to either be partial or complete. In a person with complete remission, all signs of cancer have disappeared.. A cancer is referred to as cured when there are no traces of cancer left in the body following treatment. If youve been in complete remission for 5 years or moreTrusted Source, your doctor may say that your cancer has been cured.. However, some cancer cells can remain present in the body following treatment. Because of this, its possible that the cancer can return at some point.. Due to this risk, your doctor may continue to monitor you for many years to make sure your cancer hasnt returned.. Various factors, such as the stage of the cancer and treatment response, can influence whether a cancer goes into remission. Its ...
I have terrible terrible anxiety that comes and goes, search for a new therapist is on the agenda. I keep having bouts of nausea (NO NOT PREGNANT) at night that sometimes end up with me getting sick because I just cant seem to calm down. There are so many people that dont make it to the remission phase of treatment but there wasnt this HUGE HUGE weight that was lifted off of my shoulders like I had thought there would be. During the day I am so busy with the girls that Im totally fine but once its time to settle down and go to sleep my mind just keeps playing tricks on me. What if they didnt kill ALL of the cancer? And its not just cancer, its thinking about driving in the car with the girls, what if someone hits us? What if my kid runs out into the road and gets hit? I cant live my life fearing things that might happen and Im doing the best I can to not worry but it just doesnt stop. It never stops. Im not so sure that it ever will. For right now were going from moment to moment ...
Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical Oncology. Cancer is considered relapsed when disease returns after it has been in remission following treatment, meaning that signs and symptoms have disappeared. Preventing relapse-or […]. ...
Some of the factors which seem to be important in successful chemotherapy are (a) extent of disease, (b) measurability of disease, (c) availability of an effective drug for remission induction, (d) treatment during remission, and (e) treatment related to the proliferative state of the tumor. Chemotherapy of such important tumors as carcinoma of the lung, breast, or colon is considered in relation to these factors. These considerations suggest the need for clinical studies aimed at creating successes out of failures. Treatment should be begun when there is minimal tumor present, preferably immediately after surgery. Multiple long-term chemotherapy in remission should be employed. Such studies are based on sound scientific principles and are urgently needed.. ...
I was curious if anyone understands or could explain the mechanism of how IVIG could put my MCAS into remission? I use the word remission versus...
For the second time, doctors are reporting that a patients HIV has gone into sustained remission following a stem cell transplant-leaving him effectively cured of the disease.
For some, continued medical care is needed. Medical checkups, tests, and other health care monitoring recommended and prescribed by your doctor and medical care team needs to be taken seriously and followed. This can range from emotional counseling to physical therapy and all forms of continued care are important to your healing and survivorship journey. These appointments can cause some anxiety and worry. Continued care after your cancer has been beaten into remission can still bring on the worry that it could come back. It can be hard to change care teams and doctors for this continued care when youre already so used to the one youve had this whole time. If you are feeling this way, feeling anxious, or feeling worried, it is important to talk about these concerns with your current care team, family members, and potential new care team. Putting continued care first and making it a priority in your life allows you to stay ahead of what could become. It can also help you remain productive and ...
The 34-year-old Brazilian, who was diagnosed with HIV in 2012, has achieved long-term remission after treatment for less than a year
This is from another Townhall meeting that I did with Dave Berg back in 2000. I followed his protocol concurrent with Cecil Jadins protocol for pathogens and went into full remission for 11 years. Both Berg and Jadin cites that relapse can happen, but with an ability to reduce the risk. March 26th, 2000 [David]…
Six-year-old Erin Cross parents raised $180,000 to send her to the US for experimental leukemia treatment. She is now in remission.
Many families with a child in remission feel empowered to make lifestyle changes that could benefit their childs health in the future. Here are some tips.
Everyone is different, Im trying to gauge my own illness and would like to hear from others experiences. Ill start with a positive. In remission do...
Jeremy Mansfield, who hosts The Rude Awakening on 94.7 Highveld Stereo, has announced that the cancer he was diagnosed with last year is in remission.
(KudoZ) English to Italian translation of spend more time in remission: allungare/prolungare i tempi di remissione [PHARMACEUTICALS - Medical: Pharmaceuticals (Medical)].
In population with CRP ≥ 10 mg/L at baseline; Time to disease progression up to and including Week 26; Proportion of patients with clinical remission at Week 26; Proportion of patients with IBDQ response at Week 26; F-36 sub-scores and change from ...
THURSDAY, SEPTEMBER 13, 2007 09:12 PM, CDT Today was probably the first day since the relapse that I really do have a lot of hope. Where do I start...
Dropped kerbs sometimes werent quite dropped enough either, meaning we had to reverse over some so that the larger wheels could negotiate it. Once we parked in a car park that when we tried to cross the road from it, we realised the kerb wasnt dropped opposite it, and rather that it was dropped 150m further down the road. This meant I had to be pushed down the middle of the road, with my Mum running as fast as she could behind me: not exactly ideal ...
TY - JOUR. T1 - Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. AU - Watanabe, Reiko. AU - Murata, Mitsuru. AU - Takayama, Nobuyuki. AU - Tokuhira, Michihide. AU - Kizaki, Masahiro. AU - Okamoto, Shinichiro. AU - Kawai, Yohko. AU - Watanabe, Kiyoaki. AU - Murakami, Hiroshi. AU - Kikuchi, Masao. AU - Nakamura, Shin. AU - Ikeda, Yasuo. PY - 1997/4. Y1 - 1997/4. N2 - Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin ...
This study proposes a nontoxic immunotherapeutic approach to extend overall survival in patients in complete remission. Most patients with ovarian cancer achieve complete clinical remission after optimal debulking surgery and first-line platinum-based chemotherapy. However, most patients, despite high response rates to first-line treatment, will relapse and undergo subsequent chemotherapy. Generally, the progression-free interval between treatments becomes shorter with each relapse, and the patient eventually dies of the disease.. For production of Cvac, each patients cells were enriched using cell separation techniques. The patients cells were cultured for 5 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) in AIM V® serum-free tissue culture medium (Thermo Fisher Scientific) to cultivate the growth of dendritic cells (DC). The culture was pulsed overnight with the antigen (mannosylated mucin 1 fusion protein [M-FP]) to arm the DCs to the specific ...
Free Online Library: Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens/Konsolidaciona terapija akutne mijeloidne leukemije: visoke doze citozinarabinozida naspram drugih konsolidacionih rezima sa citozin-arabinozidom.(Original study/Originalni naucni rad, Report) by Medicinski Pregled; Health, general Science and technology, general Acute myelocytic leukemia Drug therapy Research Cancer regression Cytarabine Health aspects
Human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) as a postremission treatment for standard risk Philadelphia chromosome-negative acute lymphoblastic leukemia (SR Ph-ALL) in the first complete remission (CR1) has not been defined. In this multicenter, phase 3 study (NCT02042690), of the 131 consecutive Ph-ALL young adult patients (YA, aged 18-39 years) without high-risk features who achieved CR1, 114 patients without HLA-matched donors received consolidation with an adult chemotherapy regimen (n = 55) or haplo-SCT (n = 59). In the landmark analysis, haplo-SCT resulted in a lower 2-year cumulative incidence of relapse (CIR, 12.8% vs 46.7%, P = 0.0017) and superior 2-year leukemia-free survival (LFS, 80.9% vs 51.1%, P = 0.0116) and 2-year overall survival (OS, 91.2% vs 75.7 [64.8-93.2] %, P = 0.0408) than chemotherapy. In the time-dependent multivariate analysis with propensity score adjustment, postremission treatment (haplo-SCT vs chemotherapy) was an independent risk
This study demonstrates evidence of subclinical disease activity in JIA patients in clinical remission by MRI. One study that used ultrasound to longitudinally evaluate JIA patients with inactive disease showed that 100% of JIA patients that had a subsequent disease flare had evidence of previous subclinical synovial hypertrophy (33). Although this study was published only in abstract form, the results suggest that subclinical disease is clinically significant in JIA. In another study that compared 2 definitions of remission in the same RA cohort (a more strict definition of remission versus DAS28 remission), there was no change in the proportion of joints that had subclinical disease detected by sonography (18). In our study, 82% of the JIA patients met the preliminary criteria for clinical remission or clinical remission on medication. The 2 patients that did not meet the remission criteria due to the observed physician joint count of ,0 did not have any abnormalities on MRI. This discrepancy ...
CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.s profile, publications, research topics, and co-authors
Patients who after completion of consolidation therapy remain permanently PCR-positive or suffer a molecular or hematological relapse still have an about 50 percent chance to attain a stable remission with second-line therapy. Due to its high antileukemic efficacy and favorable toxicity profile ATO is currently considered as the therapy of choice in the treatment of relapses. Usually induction therapy consists of one course of ATO, followed by a consolidation course of ATO which might be combined with ATRA. Post-remission therapy is recommended to stabilize the new remission. Selection of post-remission treatment depends on the individual case. In molecular remission, and in the presence of a PCR-negative transplant, the rates of long-term remission after autologous and allogeneic PBSCT were found to be equivalent. An allogeneic transplantation should be performed if the transplant is PCR positive. If transplantation is not feasible either therapy with ATO, chemotherapy, or a combination of both ...
This study investigated azacitidine in patients older than 60, with acute myeloid leukemia, who are in complete remission following initial chemotherapy, live
Adult ALL is a malignant disease or cancer of the blood characterized by the rapid uncontrolled growth of abnormal, immature white blood cells known as lymphoblasts. There are approximately 5,000 new cases of Adult ALL each year in the US with approximately 1500 deaths.. There has been significant progress in treating adult ALL over the past two decades and currently 60-80% of patients will achieve a complete remission following combination chemotherapy induction and 30-40% will become long-term survivors and possibly cured. This progress has been made possible by the development of effective multi-agent chemotherapy regimens; the development of Gleevec® (imatinib), which is effective in Philadelphia chromosome-positive ALL; improvements in supportive care with growth factors such as Neupogen® (Filgrastim) and Neulasta® (pegfilgrastim); and improvements in allogeneic stem cell transplantation. The development of cytogenetic and molecular tests can now better define prognostic groups allowing ...
Acute myeloid leukemia (AML) is the most lethal hematological malignancy, and the occurrence of chemoresistance prevents the achievement of complete remission following the standard therapy. MicroRNAs have been extensively investigated as critical regulators of hematopoiesis and leukemogenesis, and they represent a promising strategy for AML therapy. In this study, we identified miR-34b as a novel regulator in myeloid proliferation and apoptosis of leukemic cells. We found that miR-34b was developmentally upregulated in plasma and myeloid cells of healthy subjects, while it was significantly reduced in blood samples of patients with AML and AML cell lines. Moreover, the miR-34b mimicked transfection-mediated restoration of miR-34b inhibited cell viability and promoted cell apoptosis of HL-60 and OCI-AML3 cell lines. Using a miRNA predicting algorithm miRanda, we selected a potent target heat shock transcription factor 1 (HSF1) since that is a master regulator of the heat shock response and is associated
TY - JOUR. T1 - Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. AU - Silverman, Lewis B.. AU - Supko, Jeffrey G.. AU - Stevenson, Kristen E.. AU - Woodward, Christina. AU - Vrooman, Lynda M.. AU - Neuberg, Donna S.. AU - Asselin, Barbara L.. AU - Athale, Uma H.. AU - Clavell, Luis. AU - Cole, Peter D.. AU - Kelly, Kara M.. AU - Laverdière, Caroline. AU - Michon, Bruno. AU - Schorin, Marshall. AU - Schwartz, Cindy L.. AU - OBrien, Jane E.. AU - Cohen, Harvey J.. AU - Sallan, Stephen E.. PY - 2010/2/18. Y1 - 2010/2/18. N2 - Over the past several decades, L-asparaginase, an important component of therapy for acute lymphoblastic leukemia (ALL), has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis.We evaluated the feasibility of giving polyethylene glycosylated (PEG)-asparaginase, the polyethylene glycol conjugate of Escherichia coli ...
Manuscript abstract: IMPORTANCE: |50% of patients with new-onset type 1 diabetes (T1D) do not enter partial clinical remission (PCR); early identification of these patients may improve initial glycemic control and reduce long-term complications. AIM: To determine whether routinely obtainable clinical parameters predict non-remission in children and adolescents with new-onset T1D. SUBJECTS AND METHODS: Data on remission were collected for the first 36 months of disease in 204 subjects of ages 2-14 years with new-onset type 1 diabetes. There were 86 remitters (age 9.1±3.0y; male 57%), and 118 non-remitters (age 7.0±3.1y; male 40.7%). PCR was defined as insulin-dose adjusted hemoglobin A1c of ≤9. RESULTS: Non-remission occurred in 57.8% of subjects. Univariable analysis showed that the risk for non-remission was increased 9-fold in patients with 4 diabetes-associated auto-antibodies (OR = 9.90, p = 0.010); 5-fold in patients(odds ratio = 5.38, p = 0.032), 3-fold in those with bicarbonate of/dL at
Three of nine patients (33%) remain in complete clinical remission at 25, 38, and 52 months, respectively. The cancer-testis antigen NY-ESO-1 is expressed in greater than 40% of advanced epithelial ovarian cancers and represents a promising immunotherapeutic target. In a small Phase I (safety and immunogenicity) clinical trial conducted by Memorial Sloan-Kettering Cancer Center and…
HOUSTON-Adding rituximab (Rituxan) to standard chemotherapy increased complete remission (CR) rates for chronic lymphocytic leukemia (CLL) and reduced the number of bone marrow cells expressing the CLL-associated cell-surface markers CD5 and CD19, according to Michael J. Keating, MD. Fludarabine, cyclophosphamide, and rituximab (FCR) is the most active regimen explored by our group in previously untreated CLL, and the toxicity profile is similar to that seen with FC alone, said Dr. Keating, professor of leukemia developmental research at the University of Texas M. D. Anderson Cancer Center in Houston. 1
Background Sufferers with newly diagnosed acute myeloid leukemia (AML) frequently have residual leukemia in the bone tissue marrow on time 10-14 following the begin of induction therapy. therapy. Strategies Patients signed up to 6 consecutive research for AML executed with the Eastern Cooperative Oncology Group (ECOG) between 1983 to 1993 had been treated with induction therapy. If your day 14 bone tissue marrow acquired residual leukemia sufferers had been to receive another cycle of similar induction therapy. All sufferers who attained CR after a couple of cycles received exactly the same post-remission therapy. LEADS TO each one of the 6 research the long-term final result was very similar for sufferers requiring a couple of cycles of induction to attain MLN2480 CR which was unbiased of various other prognostic variables such as for example age group or karyotype. To conclude The current presence of residual leukemia per day 10-14 bone tissue marrow will not predict for the worse prognosis if ...
He was only diagnosed Nov 09 and we were referred to a fairly new consultant at the hospital who had used enteral nutrition at his previous hospital(with good results) and he was of the opinion that it would be better to give that a try first rather than hit him with the steroids. The pain stopped and he did gain those couple of pounds but when food was re-introduced he did get the sort of feeling he used to get before the pain came so he was then put onto steroids(now tapering of). He then packed on around 14lb in 3 weeks although at this point not to sure whether this is down to the steroids giving him an increased appetite, and/or fluid retention all whether the shakes are doing their bit. The past couple of weeks his weight has remained unchanged(despite eating any/everything) They want him to put on at least another 11/13 lb. He is painfree though( End of May till middle of July is big exam time for him-just hope the stress doesnt knock him back again)Like your daughter his energy is up too ...
Consolidation treatment for acute lymphoblastic leukemia (ALL) (costs for program #150961) ✔ University Hospital Münster ✔ Department of Hematology, Hemostaseology, Oncology and Pneumology (Medical Department A) ✔ BookingHealth.com
Results 281 patients (68% female; mean DAS 3.4, median HAQ 1.00) were included. During 1 year of follow-up, 129 of 281 (46%) patients (group A: 90 (49%), group B: 39 (40%)) attained remission at 2 consecutive visits. 76/281 (27)% achieved remission within 6 months. Univariate analyses revealed that female sex was associated with a lower chance of attaining remission (demographic factors). Similar relations were observed for higher DAS, HAQ and worse physical functioning (disease factors) and higher levels of anxiety, depression, fatigue and passive coping with pain and lower levels of mental functioning and internal locus of control (psychosocial factors). In multivariate analyses, female sex, treatment and higher levels of fatigue were associated with a lower chance to attain remission within 6 months, whereas older age, female sex and higher levels of depression were associated with increased time to remission within 12 months. ...
Cancer Research UK Cancer Research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature today (Sunday).. The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill cancer cells by damaging DNA. When the researchers removed FAK from blood vessels that grew in melanoma or lung cancer models, both chemotherapy and radiation therapies were far more effective in killing the tumors.. The researchers also studied samples taken from lymphoma patients. Those with low levels of FAK in their blood vessels were more likely to have complete remission following treatment. This suggests that developing drugs to strike out FAK in cancer blood vessels may boost cancer treatments and prevent cancer from coming ...
In a prospective multicenter study, 368 acute lymphoblastic leukemia (ALL) patients aged 15 to 65 years were treated with an intensified induction and reinduction regimen; 272 (73.9%) achieved complete remission (CR). The median remission duration (MRD) is 24.3 months, and the probability of being in continuous CR (CCR) at greater than 5 years is .37. The median survival for all 368 patients is 27.5 months, and the probability of being alive at 5 years is .39. For the 272 patients in remission the median survival is 58.4 months, and the probability of being alive at 5 years is .49. A lower CR rate was seen for patients with bleeding at diagnosis or with splenomegaly/hepatosplenomegaly. The prognostic factors unfavorable for remission duration were time to CR greater than 4 weeks v less than 4 weeks (P = .0002), age greater than 35 years v less than 35 years (P = .0008), leukocyte count greater than 30,000/microL v less than 30,000/microL (P = .0112), and null ALL v common ALL (c-ALL)/T cell ALL ...
Remission is a term used to indicate that there is no longer any detectable inflammatory disease activity. The use of the term remission implies that the disease may not be cured, and that relapses are possible in the future. Once a state of remission has been achieved the intensity of immunosuppressive therapy is usually reduced. This means that the dose of prednisone is reduced and that the first-line remission-induction agent (such as cyclophosphamide) is replaced by better-tolerated, milder forms of immunosuppression that are used more long-term to keep the patient in remission (such as methotrexate, azathioprine, or mycophenolate mofetil).. Remission does not necessarily mean that the patient is feeling perfectly well. This is because symptoms may be caused by either active inflammation associated with vasculitis, or by organ damage resulting from active disease or by side effects of medications used to put the patient in remission. Remission also does not mean that all serological ...
Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone marrow were analyzed using targeted capture DNA sequencing. We analyzed the association between mutation clearance (MC) on the basis of variant allele frequency (VAF) at CR (MC2.5: if the VAF of residual mutations was < 2.5%; MC1.0: if the VAF was < 1%; and complete MC [CMC]: if no detectable residual mutations) and event-free survival, overall survival (OS), and cumulative incidence of relapse (CIR). Results MC1.0 and CMC were associated with significantly better OS (2-year OS: 75% v 61% in MC1.0 v non-MC1.0; P = .0465; 2-year OS: 77% v 60% in CMC v non-CMC; P = .0303) and lower CIR (2-year ...
Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.
Patients with MDS who are unable or unwilling to undergo a stem cell transplant using donor cells or those planning to have their own stem cells collected for a future transplant can receive conventional chemotherapy without stem cell support. While many patients have a remission with this type of treatment, most ultimately experience disease progression. While some patients may experience a long remission following therapy, remissions after conventional chemotherapy typically average less than 12 months.. Because most patients with MDS are over 65 years of age and cannot tolerate the side effects of conventional chemotherapy, lower doses of chemotherapy may be beneficial.. Vidaza® (azacitadine): In May of 2004, the U.S. Food and Drug Administration (FDA) approved Vidaza for the treatment of MDS. Vidaza is the first drug to be approved specifically for the treatment of MDS.. Results of a clinical trial that compared Vidaza to supportive care in the treatment of 191 patients with MDS ...
Fixing Leaky Gut Helps ME/CFS, and Sometimes Achieves Full Remission In a ME/CFS patient, Michael Maes found that treatment with anti-inflammatories,...
Ten (10) patients with uncontrolled persistent moderate to severe CD were treated with QBECO through a compassionate use program. Patients may have continued to receive conventional medical treatments and/or complementary therapies in addition to the SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of QBECO treatment of three months or more. Four of these patients have had sustained clinical remission after discontinuing all medications including SSI treatment. The longest case of clinical remission reported is still ongoing, after almost 3 years. Three of the seven patients reporting full remission had follow-up colonoscopies or CT scan with confirmation of full remission. Nine of the ten patients were able to discontinue all other medications at some point while on QBECO treatment. (More information here: http://www.qucrohnstrial.com/ssi-int...cy-and-safety/ ...
This randomized study with a run-in dose-selection phase will be investigating lenalidomide in combination with standard remission-induction chemotherapy and
[RAEB in transformation in continuing complete remission by small doses of cytarabin]. - T Yamada, N Sueoka, Y Tanabe, K Dan, S Kuriya, T Nomura, T Shiomura
Biology Assignment Help, Maintenance therapy for leukemia, Maintenance Therapy A complete remission implies a clinical, haematological and bone marrow remission. For remission therapy drugs like, methotrexate cyclophospharnide and 6-mercaptopurine are used. Usually a combination of two drugs is employ
Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical Oncology. Cancer is considered relapsed when disease returns after it has been in remission following treatment, meaning that signs and symptoms have disappeared. Preventing relapse-or […]. ...
Hi everybody. Ive used to be a regular here for many years. Long time. At least 20 years I think. Psychobabble was a brand new thing back when I first joined. I just wanted to share hope and faith with everybody here that cure and remission are possible. While each persons journey is unique and different depending on their own genetics and experiences, I believe the causes of chronic resistant major depression and its associated syndromes - anxiety, schizophrenia - are not idiopathic. Thats a fancy medical word that means doctors have no idea why it happens - many medical terms come from Greek and this one came from the word idiot. Most doctors approach depression as idiopathic and do not make much of an effort to figure out what the actual cause of the symptoms are. This is why we all get so sick. The doctors are looking to help you with relief, but they honestly have no clue how you got sick in the first place or how to do make you un-sick. The best they can do, usually, is try to help you ...
Hi everybody. Ive used to be a regular here for many years. Long time. At least 20 years I think. Psychobabble was a brand new thing back when I first joined. I just wanted to share hope and faith with everybody here that cure and remission are possible. While each persons journey is unique and different depending on their own genetics and experiences, I believe the causes of chronic resistant major depression and its associated syndromes - anxiety, schizophrenia - are not idiopathic. Thats a fancy medical word that means doctors have no idea why it happens - many medical terms come from Greek and this one came from the word idiot. Most doctors approach depression as idiopathic and do not make much of an effort to figure out what the actual cause of the symptoms are. This is why we all get so sick. The doctors are looking to help you with relief, but they honestly have no clue how you got sick in the first place or how to do make you un-sick. The best they can do, usually, is try to help you ...
Complete Remission Unconfirmed Complete Remission Rate 3.5 Fold Higher Compared to Standard Chemotherapy Cell Therapeutics, Inc. (CTI) announced today that it a
ATLANTA - An investigational oral targeted agent called lestaurtinib (CEP-701), a FLT3 kinase inhibitor, can enhance the likelihood of complete remissions, compared with chemotherapy alone, for poor-p
to quell the reaction.. Eight days later, his leukemia was gone. Even the doctors were shocked, Dr. Brentjens said. They repeated the lab tests just to make sure there was no mistake.. Once he was in remission, Mr. Aponte had a bone-marrow transplant, as did three of the other patients in the study. Another had medical problems that made a transplant impossible, and it was he who relapsed and died. The researchers think he may have relapsed because the steroids he needed to treat the cytokine storm may have wiped out the T-cells before they could do their job.. For the other patients, it is not known whether the transplants were really needed; in theory, the T-cells alone might have produced a long-term remission or even a cure. Patients treated at the University of Pennsylvania were not given transplants, and most have stayed in remission. But the technique used there involves a different viral vector and different genetic programming from the one at Sloan-Kettering. ...
Complete remission means that there are no cancer cells found in the body based on tests, physical exams and scans of the body, according to WebMD. This can also be referred to as No Evidence of...
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference
Collagen Induction Therapy in Conshohocken, PA. Collagen Induction Therapy is back, taking many from age related wrinkles to new looking skin.
Changes in clinical and functional state of children with asthma in period of remission, wich demonstrate persistant damage of bronchial mucosa on data of - umj.com.ua
Two recent case reports of temporary HIV remission, first presented at this years CROI and IAS conferences, have now been published in the open access ...
One of the most complicated conditions to deal with is multiple sclerosis. When the bodys own immune system starts attacking the Central Nervous System, reversing the effects can be very difficult. However, there seems to be a ray of hope in the treatment of the problem according to leading researcher, Dr. Shiva Gopal Vasishta. He states that when a high dosage of immunosuppressive therapy is given together with transfusing the patient with their own stem cells, it induces a long-term remission of sclerosis.. A lot of research has been carried out on people that have used the therapy. The findings indicated that people who used the therapy and got a HDT transplant got a remission and that up to five years after the treatment, their disability had not progressed. The patients also did not get any new brain lesions, something that is characteristic of people with MS patients. There have been other studies which have shown that other medications used in the treatment of the condition have had ...
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood. 2019 Nov 13; 134(Supplement_1):48 ...